Is DePuy owned by Johnson&Johnson?
DePuy Synthes (/ dəˈpjuː /) is a franchise of orthopaedic and neurosurgery companies. Acquired by Johnson & Johnson in 1998, its companies form part of the Johnson & Johnson Medical Devices group. DePuy develops and markets products under the Codman, DePuy Mitek, DePuy Orthopaedics and DePuy Spine brands.
When did Johnson and Johnson buy Synthes?
Johnson & Johnson Announces Completion of Synthes Acquisition. Combination Creates the World's Leading Orthopaedics Business. New Brunswick, NJ (June 14, 2012) – Johnson & Johnson today announced the completion of the acquisition of Synthes, Inc. for a total purchase price of $19.7 billion in cash and stock.
What countries does DePuy operate in?
DePuy is now operating from several countries, including the United Kingdom, Japan, France, Germany, Ireland and Australia. In many other countries, DePuy operates as a brand under the Johnson & Johnson Medical organization.
What does the Synthes-DePuy deal mean for orthopaedics?
"The combination of these two respected leaders -- Synthes and DePuy -- will enable us to better serve clinicians and patients worldwide, bring new innovations to the marketplace in orthopaedics and neurologics, and strengthen our ability to compete in developing markets."
See more
When did Johnson and Johnson acquire DePuy?
Jul. 21, 1998Johnson & Johnson acquires DePuy for $3.5B - Jul. 21, 1998.
Who is DePuy Synthes owned by?
Johnson & JohnsonDePuy Synthes (/dəˈpjuː/) is a franchise of orthopaedic and neurosurgery companies. Acquired by Johnson & Johnson in 1998, its companies form part of the Johnson & Johnson Medical Devices group. DePuy develops and markets products under the Codman, DePuy Mitek, DePuy Orthopaedics and DePuy Spine brands.
What happened to Synthes?
In June 2012 Synthes was sold by its chairman, former CEO and largest shareholder Hansjörg Wyss to Johnson & Johnson for $20.2 billion. It is now part of their DePuy Synthes division.
Is DePuy Synthes part of Johnson and Johnson?
DePuy Synthes, part of the Johnson & Johnson Medical Devices Companies, provides one of the most comprehensive orthopaedics portfolios in the world.
How much do DePuy Synthes reps make?
The average DePuy Synthes Sales Rep earns an estimated $177,364 annually, which includes an estimated base salary of $96,319 with a $81,045 bonus. DePuy Synthes' Sales Rep compensation is $66,836 more than the US average for a Sales Rep. Sales Rep salaries at DePuy Synthes can range from $90,000 - $270,000.
How much do DePuy sales reps make?
The estimated total pay for a Sales Representative at DePuy Synthes is $135,449 per year. This number represents the median, which is the midpoint of the ranges from our proprietary Total Pay Estimate model and based on salaries collected from our users. The estimated base pay is $73,911 per year.
Who is DePuy Synthes competitors?
See how Depuy Synthes compares to similar products. Depuy Synthes's top competitors include Arthrex, Vexim, and Ortho Development. Arthrex is a global medical device company that specializes in new product development and medical education in orthopedics.
Did Johnson buy Johnson DePuy?
As part of Johnson & Johnson, DePuy continues to innovate. Founded in 1895 by chemist and pharmaceutical salesman Revra DePuy, DePuy was the world's first orthopaedics company.
Who is the CEO of DePuy Synthes?
David BakerDavid Baker serves as the CEO / President of DePuy Synthes.
How old is DePuy?
Founded in the 1890s in Indiana by a travelling salesman, DePuy Manufacturing started out making fibre splints to set fractures. 125 years later, DePuy Synthes is owned by J&J and is one of the world's leading orthopaedic businesses.
Is DePuy Synthes a good company to work for?
Overall, 81% of employees would recommend working at DePuy Synthes to a friend. This is based on 663 anonymously submitted reviews on Glassdoor. How do job seekers rate their interview experience at DePuy Synthes? 68% of job seekers rate their interview experience at DePuy Synthes as positive.
What is DePuy Synthes known for?
DePuy Synthes, The Orthopaedics Company of Johnson & Johnson, offers the world's most comprehensive portfolio of orthopaedic and medtech solutions to Keep People Moving.
Did Johnson and Johnson Buy DePuy Synthes?
Johnson & Johnson acquired the Swiss company Synthes, a pioneer in orthopaedic medical devices. This business was combined with DePuy to form DePuy Synthes.
Did Johnson buy Johnson DePuy?
As part of Johnson & Johnson, DePuy continues to innovate. Founded in 1895 by chemist and pharmaceutical salesman Revra DePuy, DePuy was the world's first orthopaedics company.
Who is the CEO of DePuy Synthes?
David BakerDavid Baker serves as the CEO / President of DePuy Synthes.
Who is DePuy Synthes competitors?
See how Depuy Synthes compares to similar products. Depuy Synthes's top competitors include Arthrex, Vexim, and Ortho Development. Arthrex is a global medical device company that specializes in new product development and medical education in orthopedics.
How long has Depuy Synthes been in operation?
With DePuy Synthes reaching the milestone of 125 years of operation in 2020, we look back at the fascinating history of this orthopaedic giant.
Where is Depuy Synthes based?
DePuy’s decision to base his company in Warsaw, Indiana is central to why the city is now hailed as the orthopaedics capital of the world. DePuy Synthes’ joint reconstruction business is still based there.
What is the name of the orthopaedic company that is integrated into Depuy?
As a result of the deal, Synthes was integrated into the DePuy franchise. The company was renamed DePuy Synthes and it became the world’s largest orthopaedic company.
What did Depuy sell off?
A few years later, DePuy sold off its soft goods arm and decided to focus on implants, as well as spinal and trauma products.
What happened to Synthes and Norian?
Synthes and its subsidiary Norian had previously plead guilty in 2009 to illegally selling a bone void filler for unapproved uses and failing to properly report deaths and adverse events related to the product.
When did Depuy recall hip implants?
After a similar situation emerged with another of DePuy’s ASR hip implants, the company moved to recall all of those products from the Australian market in 2009 and then the rest of the world in 2010. DePuy stated it would cover “reasonable and customary costs of monitoring and treatment for services, including revision surgeries, associated with the recall of ASR”.
When were pinnacle hip implants first approved?
At the same time, DePuy and J&J were also grappling with lawsuits surrounding failures of its Pinnacle hip implants, which were first FDA approved in 2000 and had a similar metal-on-metal design to the ASR products.
Dive Brief
Johnson & Johnson announced Thursday that DePuy Synthes, the healthcare giant's orthopaedics company, has acquired CrossRoads Extremity Systems for an undisclosed amount.
Dive Insight
J&J's CrossRoads acquisition comes just weeks after the company told investors that it would be more aggressive on the M&A front going forward. Executives said in January that the company will be more active in deal-making for both the pharmaceutical and medical devices businesses.
Recommended Reading
Select user consent: By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime.
What are Synthes and DePuy's market trends?
These include an aging population, patient desire to remain active, increasing rates of obesity and the resulting impact on joint disease, growing treatment demands in emerging markets, and a movement toward earlier intervention.
What is the difference between Synthes and DePuy?
DePuy offers one of the most diverse orthopaedics portfolios in the industry, while Synthes is recognized for its innovations in trauma, spine, cranio-maxillofacial and power tools. Together, the companies will offer surgeons and patients a unique breadth and depth of technology and service worldwide to meet their orthopaedic needs.
Who owns Synthes?
New Brunswick, NJ, and West Chester, PA (USA) (April 27, 2011) – Johnson & Johnson (NYSE: JNJ), the world’s most comprehensive and broadly-based manufacturer of health care products, and Synthes, Inc. (SWX:SYST.VX), a premier global manufacturer of orthopaedic devices, today announced that they have entered into a definitive agreement whereby Johnson & Johnson will acquire Synthes for CHF159 per share, or $21.3 billion. Upon completion of this transaction, Synthes and the DePuy Companies of Johnson & Johnson together will comprise the largest business within the Medical Devices and Diagnostics segment of Johnson & Johnson.
What are the interests of synthes?
Certain executive officers and directors of Synthes have interests in the proposed transaction that may differ from the interests of stockholders generally, including benefits conferred under retention, severance and change in control arrangements and continuation of director and officer insurance and indemnification.
